Purpose: There is a need to evaluate the treatment response in patients who have undergone radioiodine treatment (RIT) for differentiated thyroid cancer. Our study aimed to show thyroid hormone withdrawal (THW) effects on quality of life and psychological symptoms in female patients with low-risk, well-differentiated papillary thyroid cancer. Methods: We applied the short form-36 (SF-36) and Symptom Checklist-90-R (SCL-90-R) questionnaires to the patients in the euthyroid state who have referred a median of 9 months (6-13 months) after RIT to perform a diagnostic whole-body scan (dWBS) and to evaluate stimulated Tg. We applied the same questionnaire again when thyroid-stimulating hormone (TSH) was > 30 μIU/mL 4 weeks after THW (hypothyroid state). We evaluated the changes in questionnaire scores using the paired-samples t-test or the Wilcoxon signed-rank test. Results: Our study included 52 patients (median age 48 years, range 23-65 years). There was a statistically significant worsening in anxiety, psychosis, additional items, and general symptom index symptoms with the SCL-90-R questionnaire, physical functioning, role limitation due to physical health, energy/fatigue, emotional well-being, social function, general health, and health change with the SF-36 questionnaire. Conclusions: THW worsened the patients' psychological symptoms and quality of life. Thyrotropin alfa is an alternative to reduce side effects, but it can be costly and difficult to obtain in developing countries. In order to reduce the side effects of hypothyroidism and avoid the high cost, treatment response assessment can be done only in selected patient groups.

Background We aimed to evaluate patients with nasopharyngeal carcinoma (NPC) in a nonendemic population. Methods In a national, retrospective, multicenteric study, 563 patients treated with intensity modulated radiotherapy at 22 centers between 2015 and 2020 were analyzed. Results Median age was 48 (9–83), age distribution was bimodal, 74.1% were male, and 78.7% were stage III‐IVA. Keratinizing and undifferentiated carcinoma rates were 3.9% and 81.2%. Patients were treated with concomitant chemoradiotherapy (48.9%), or radiotherapy combined with induction chemotherapy (25%) or adjuvant chemotherapy (19.5%). After 34 (6–78) months follow‐up, 8.2% locoregional and 8% distant relapse were observed. Three‐year overall survival was 89.5% and was lower in patients with age ≥50, male sex, keratinizing histology, T4, N3 and advanced stage (III‐IVA). Conclusions Patients with NPC in Turkey have mixed clinical features of both east and west. Survival outcomes are comparable to other reported series; however, the rate of distant metastases seems to be lower.

Amaç: Çalışmamızda 11 Mart 2020 ile 30 Mayıs 2020 (Karantina) ve 11 Mart 2019 ile 30 Mayıs 2019 (Karantina öncesi) arasında tanı alan meme kanseri hastalarını klinik ve patolojik özellikler açısından karşılaştırmayı amaçladık. Materyal ve metod: 23'ü karantina döneminde ve 47'si karantina öncesi dönemde olmak üzere toplam 70 hasta retrospektif olarak değerlendirildi. Menopoz durumu, semptom varlığı, ameliyatın türü, hormonal alt gruplar, kemoterapinin amacı, T, N, M evreleri çapraz tablolar kullanılarak gruplara ayrıldı. Gruplar arasındaki farklılıklar Ki-kare testleri kullanılarak karşılaştırıldı. Bulgular: Çalışmamızda, karantina döneminde hasta sayısı karantina öncesi döneme göre daha azdı. Karantina dönemindeki ve karantina öncesi dönemdeki yaş, menopoz durumu, tedaviye başlama zamanı, tarama oranı, hormonal alt tip, ameliyat tipi, T, N, M evresi gibi değişkenlerde anlamlı bir fark bulunmadı. Sonuç: Karantina döneminde hasta sayısı karantina öncesi döneme göre daha azdı. Meme kanseri hastalarında karantina süresi ile aynı dönemden bir yıl önceki zaman aralığı arasında klinik bir fark saptanmadı.